Timothée Olivier, MD
Enriched profileMédecin adjoint agrégé (attending physician), Service d'oncologie, Département d'oncologie, HUG, since 1 November 2023 · Geneva University Hospitals (HUG)
Timothée Olivier is Médecin adjoint agrégé (attending physician), Service d'oncologie, Département d'oncologie, HUG, since 1 November 2023 at Geneva University Hospitals (HUG). OpenAlex indexes 127 publications with 2,019 citations (h-index 23).
Data verified 8 Nov 2026
Overview
Updated 8 Nov 2026
Timothée Olivier is Médecin adjoint agrégé (attending physician), Service d'oncologie, Département d'oncologie, HUG, since 1 November 2023 at Geneva University Hospitals (HUG), Department of Oncology, Medical Oncology Service. The public record shows 127 publications with 2,019 citations (h-index 23), centered on Statistical Methods in Clinical Trials, Cancer Immunotherapy and Biomarkers, Pharmaceutical industry and healthcare.
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Statistical Methods in Clinical Trials
Generated from the cited public record · current as of 8 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintScholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications. i10-index 46.
Clinical & industry
trials, payments and federal fundingNot shown. No U.S. clinical registration on file.
Federally funded research awards.
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Contact
No public contact details on file. Research profiles have no U.S. clinical registration, so there's no federal registry record to draw an address or phone from. Why? →
Clinical trials
We didn't find any investigator roles for this person on ClinicalTrials.gov. Why? →
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 8 Nov 2026
6 congress contributions (2007–2025) across ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Why the duration of cancer treatment requires a closer look: An empirical analysis of recent FDA approvals.
ASCO Annual Meeting
ASCO2025Co-author - Updated estimates of eligibility and response: Immune checkpoint inhibitors.
ASCO Annual Meeting
ASCO2024Co-authorOnline-only - 133P Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questions
ESMO Congress
ESMO2022Co-authorPoster
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 8 Nov 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Time-of-Day Immunotherapy: Why the Field Still Needs Randomized Evidence.
Journal of clinical oncology
Article2026 - Daraxonrasib in Pancreatic Cancer: From Second-Line Breakthrough to First-Line Evidence.
Journal of clinical oncology
Article2026 - Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors.
Clinical cancer research
Review2026 - Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.
CA: a cancer journal for clinicians
Review2025
Most-cited works
by citation count (OpenAlex)Network
Updated 8 Nov 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Congress posts on X
Post links from an X account tied to this person through reviewed identity evidence.
Listed under ESMO 2026
Listed under ESMO 2026
Listed under ESMO 2026
These links cover selected congress pages. They do not establish attendance or a complete posting history. Post availability may change.
Online presence
Updated 8 Nov 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- X / Twitter
x.com/Timothee_MD
Mentions by others
where others cite or feature them- Other
hug.ch/oncologie/dr-timothee-olivier
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hug.ch ↗ - Oncodaily.com
Profiled as an OncoInfluencer to follow on social media (OncoDaily)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 8 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →consilium-scientific.org ↗
Editorial & leadership roles
journal and society appointments- Co-Editor-in-Chief
ESMO Rare Cancers
Secondary affiliations
appointments beyond the home institutionMedia & interviews
press, podcasts and appearances- Guest on the 'Bread and butter oncology' podcast
discussing recent oncology papers (episode transcript listing)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tapesearch.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Ignacio Wistuba, MD
Moffitt Cancer Center
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)